Detour (Blood Flow Recovery System)

2023: System Announcement

In mid-June 2023, Endologix launched the Detour system for the treatment of long, complex superficial femoral-positive lesions.

According to Endologix, the Detour system has become a breakthrough in the treatment of peripheral artery disease, which, according to WHO estimates, affects about 6.5 million Americans over 40 years old. A group of peripheral arterial diseases characterized by peripheral arterial channel involvement that leads to oxygen and nutrient deficiency in the relevant organs. As of June 2023, the recommended therapy is open surgical bypass surgery - an invasive procedure.

There was a system for restoring blood flow in the leg without open surgical operations

The Detour system offers a new approach called percutaneous transmural arterial bypass (CHBA). The method allows for the treatment of complex peripheral artery diseases, allowing doctors to bypass lesions in the superficial femoral artery with stents mounted in the femoral vein to restore blood flow in the leg.

ChelBA therapy represents a significant step for patients with complex peripheral artery disease. People have long needed a more effective and less invasive treatment option for extended lesions. We are proud to pioneer this new approach and continue to innovate for the benefit of patients. We look forward to launching this new therapy in the U.S. through a targeted release to the market by the end of July 2023, Endologix President and CEO Matt Thompson said in a news release.

According to Endologix, this approach is particularly effective for patients with long lesions ranging from 20 cm to 46 cm in length, patients who have already undergone unsuccessful endovascular procedures, or patients who may be suboptimal candidates for open surgical bypass surgery. The Detour system adds to its legacy of innovative vascular therapies to improve patient outcomes, the developers said.^[1]

Notes